
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MT-1002
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MT-1002, designed to specifically target and kill activated CD206+ macrophages by delivering Cy3-Manocept-doxorubicin, a chemotoxin, which can kill KS tumor cells and their tumor-associated macrophages.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : MT-1002
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 18, 2022
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MT-1002
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $5.0 million
Deal Type : Private Placement
Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor
Details : MT-1002, designed to specifically target and kill activated CD206+ macrophages by delivering doxorubicin; and MT-2002, designed to inhibit the inflammatory activity of activated CD206+ macrophages by delivering a potent anti-inflammatory agent.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 02, 2021
Lead Product(s) : MT-1002
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $5.0 million
Deal Type : Private Placement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 04, 2019
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 06, 2019
Lead Product(s) : 99m-Tc Tilmanocept
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 99m-Tc Sulfur Colloid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 99m-Tc Sulfur Colloid is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
November 06, 2017
Lead Product(s) : 99m-Tc Sulfur Colloid
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tilmanocept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tilmanocept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 07, 2017
Lead Product(s) : Tilmanocept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : 99m-Tc Tilmanocept is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sarcoma, Kaposi.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 17, 2017
